Trial Profile
A Phase II Window-of-opportunity Study of Single Agent Lenvatinib in Estrogen Receptor Positive Early Stage Breast Cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Lenvatinib (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- 31 Mar 2021 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified on February 2017 by National University Hospital, Singapore)
- 02 Jun 2017 New trial record